サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1609800

日本の細胞療法市場レポート：細胞タイプ、治療タイプ、治療領域、エンドユーザー、地域別、2024年～2032年

Japan Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 121 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.84円
日本の細胞療法市場レポート：細胞タイプ、治療タイプ、治療領域、エンドユーザー、地域別、2024年～2032年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 121 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の細胞療法市場の市場規模は2023年に3億1,760万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに17億8,280万米ドルに達し、2024年から2032年の間に18.70%の成長率（CAGR）を示すと予測しています。市場を牽引する要因としては、患者の知識の増加、政府からの支援の高まり、保険適用範囲の拡大などが挙げられます。

本レポートで扱う主な質問

  • 日本の細胞療法市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が日本の細胞療法市場に与えた影響は？
  • 日本の細胞療法市場の細胞タイプ別の内訳は？
  • 日本の細胞療法市場の治療タイプ別の内訳は？
  • 日本の細胞療法市場の治療領域別の内訳は？
  • 日本の細胞療法市場のエンドユーザー別の内訳は？
  • 日本の細胞療法市場のバリューチェーンにはどのような段階がありますか？
  • 日本の細胞療法における主な促進要因と課題は何か？
  • 日本の細胞療法市場の構造と主要プレーヤーは？
  • 日本の細胞療法市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の細胞療法市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本の細胞療法市場情勢

  • 過去および現在の市場動向（2018～2023年）
  • 市場予測（2024～2032年）

第6章 日本の細胞療法市場：細胞タイプ別の内訳

  • 幹細胞
  • 非幹細胞

第7章 日本の細胞療法市場：治療タイプ別の内訳

  • 自家移植
  • 同種異系

第8章 日本の細胞療法市場：治療領域別の内訳

  • 悪性腫瘍
  • 筋骨格障害
  • 自己免疫疾患
  • 皮膚科
  • その他

第9章 日本の細胞療法市場：エンドユーザー別の内訳

  • 病院と診療所
  • 学術研究機関

第10章 日本の細胞療法市場：競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第11章 主要企業のプロファイル

第12章 日本の細胞療法市場：業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第13章 付録

目次
Product Code: SR112024A19882

Japan cell therapy market size reached US$ 317.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,782.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.70% during 2024-2032. Some of the factors driving the market include the increasing knowledge among patients, the rising backing from the government, and the widening scope of insurance coverage.

Cell therapy (CT) involves the transfer of human cells to address damage to tissues and cells, offering remedies for various medical conditions. This comprehensive approach includes various types of cells such as hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Its applications go beyond strengthening the immune system for cancer treatment and also encompass the treatment of autoimmune and infectious diseases, urinary issues, joint cartilage damage, spinal cord injuries, compromised immune systems, and neurological disorders. It plays a crucial role in the production of regenerative medicines, facilitating the creation and implementation of innovative treatments aimed at the restoration of tissues and organs and the recovery of functions affected by aging, diseases, or injuries.

Japan Cell Therapy Market Trends:

The Japan cell therapy market is primarily stimulated by the rapid progressions in biotechnology. This development is complemented by a notable increase in research and development endeavors, which are playing a significant role in the market's growth. Additionally, the influx of funding from both governmental sources and private investors is further fueling the research and commercialization of cell therapy. Furthermore, the expansion of clinical trial activities serves to authenticate the effectiveness and safety of cell therapies, thereby accelerating market expansion. The escalating prevalence of chronic and degenerative diseases is creating a demand for advanced treatment options, consequently propelling the market forward. With an aging population, there is a growing necessity for regenerative therapies tailored to age-related conditions, thus fortifying the market. Moreover, the increasing popularity of personalized cell therapies tailored to individual patients is fostering the growth of the market. Regulatory agencies are also providing clearer pathways for the approval of cell therapy, fostering a positive outlook for the market. The competitive landscape is driving innovation and diversification of cell therapy products, while the escalating incidence of rare diseases is further contributing to the market's upward trajectory.

Japan Cell Therapy Market Segmentation:

Cell Type Insights:

  • Stem Cell
  • Bone Marrow
  • Blood
  • Umbilical Cord-Derived
  • Adipose-Derived Stem Cell
  • Others
  • Non-stem Cell

Therapy Type Insights:

  • Autologous
  • Allogeneic

Therapeutic Area Insights:

  • Malignancies
  • Musculoskeletal Disorders
  • Autoimmune Disorders
  • Dermatology
  • Others

End User Insights:

  • Hospitals and Clinics
  • Academic and Research Institutes

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cell therapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cell therapy market?
  • What is the breakup of the Japan cell therapy market on the basis of cell type?
  • What is the breakup of the Japan cell therapy market on the basis of therapy type?
  • What is the breakup of the Japan cell therapy market on the basis of therapeutic area?
  • What is the breakup of the Japan cell therapy market on the basis of end user?
  • What are the various stages in the value chain of the Japan cell therapy market?
  • What are the key driving factors and challenges in the Japan cell therapy?
  • What is the structure of the Japan cell therapy market and who are the key players?
  • What is the degree of competition in the Japan cell therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cell Therapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cell Therapy Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Cell Therapy Market - Breakup by Cell Type

  • 6.1 Stem Cell
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Bone Marrow
      • 6.1.3.2 Blood
      • 6.1.3.3 Umbilical Cord-Derived
      • 6.1.3.4 Adipose-Derived Stem Cell
      • 6.1.3.5 Others
    • 6.1.4 Market Forecast (2024-2032)
  • 6.2 Non-stem Cell
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)

7 Japan Cell Therapy Market - Breakup by Therapy Type

  • 7.1 Autologous
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Allogeneic
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)

8 Japan Cell Therapy Market - Breakup by Therapeutic Area

  • 8.1 Malignancies
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Musculoskeletal Disorders
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Autoimmune Disorders
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Dermatology
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2018-2023)
    • 8.5.2 Market Forecast (2024-2032)

9 Japan Cell Therapy Market - Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2018-2023)
    • 9.1.3 Market Forecast (2024-2032)
  • 9.2 Academic and Research Institutes
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2018-2023)
    • 9.2.3 Market Forecast (2024-2032)

10 Japan Cell Therapy Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Cell Therapy Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix